SEATTLE, Feb. 28 /PRNewswire-FirstCall/ -- Dendreon Corporation will release its fourth quarter and year-end 2005 financial results on Monday, March 13, 2006. Company management will host a conference call at 1:30 p.m. PT; 4:30 p.m. ET to review financial results and provide a general corporate update. Access to the discussion may be obtained as follows:
Conference Call LIVE Access on March 13, 2006, 1:30 p.m. PT; 4:30 p.m. ET: Phone 877-502-9272 (domestic) or +1-913-981-5581 (international); Webcast connection is available through the “Investors/Webcast & Presentations” section of Dendreon’s website at www.dendreon.com. REPLAY Access: Phone replay is available for 3 days by calling 888-203-1112 (domestic) or +1-719-457-0820 (international). Passcode: 1573164 Webcast replay is available for 90 days through the “Investors/Webcast & Presentations” section of Dendreon’s website at www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company uses its experience in antigen identification, antigen engineering and antigen-presenting cell processing to produce active immunotherapy product candidates to potentially stimulate a cell-mediated immune response. PROVENGE (sipuleucel-T) is Dendreon’s lead active cellular immunotherapy in Phase 3 development for prostate cancer. The Company also discovered Trp-p8, a cold receptor and transmembrane ion channel in pre-clinical development, which is over-expressed in breast, prostate, lung and colon cancers. Dendreon expects to leverage its expertise in active immunotherapies to further expand its pipeline and create additional partnering and licensing opportunities. For more information about the Company and its programs, visit www.dendreon.com.
Dendreon Corporation
CONTACT: Monique M. Greer, Sr. Director, Corporate Communications ofDendreon Corporation, +1-206-829-1500
Web site: http://www.dendreon.com//
